Blood Protein Panel Aims to Forecast ALS Onset Years Before Symptoms

A Nature Medicine study identifies a 19-protein panel in blood plasma that predicts whether ALS-gene carriers will develop the disease within 6 months to 5 years, outperforming NEFL as a single-marker predictor and estimating time-to-onset with about a 1.6-year error. Many panel proteins relate to muscle biology, suggesting early muscle changes precede nerve degeneration. While promising, the panel is experimental, requiring validation and more accessible testing before clinical use; UK Biobank replication offered partial confirmation but with limitations due to its snapshot design.